Indicators of the persistent pro-inflammatory activation of the immune system in depression;Wykładniki przewlekłej aktywacji prozapalnej układu odpornościowego w depresji

Psychiatria Polska

Volumn 40, Issue 3, 2006, Pages 431-444

  Cubała, Wiesław Jerzy ^a   Godlewska, Beata ^a   Trzonkowski, Piotr ^b   Landowski, Jerzy ^a  

^a AM   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Aetiology of depression; Depression; Immunology

Indexed keywords

DEPRESSION; ENDOCRINE DISEASE; IMMUNE SYSTEM; INFLAMMATION; PATHOPHYSIOLOGY; REVIEW; BIOLOGICAL MODEL; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOLOGY;

DEPRESSION; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; IMMUNE SYSTEM; INFLAMMATION; MODELS, BIOLOGICAL; PITUITARY-ADRENAL SYSTEM;

EID: 33747388752     PISSN: 00332674     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Rybakowski J. Neuroimmunologia zaburzeń psychicznych. W: Bilikiewicz A, Pużyński S, Rybakowski J, Wciórka J, red. Psychiatria, t. I. Wrocław: U&P; 2002, s. 204-212.
2. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sc. 1998; 62(7): 583-606.
3. Holden RJ, Pakula IS, Mooney PA. An immunological model connecting the pathogenesis of stress, depression and carcinoma. Med. Hypoth. 1998; 51(4): 309-314.
4. Maes M. A review on the acute phase response in major depression. Rev. Neurose. 1993; 4(4): 407-416.
5. Maier SF, Watkins LR. Intracerebroventricular interleukin-1 receptor antagonist blocks the enhancement of fear conditioning and interference with escape produced by inescapable shock. Brain Res. 1995; 695 (2): 279-282.
6. Solomon GF, Moos RH. Emotions, immunity and disease. A speculative theoretical integration. Arch. Gen. Psychiatry 1964; 11: 657-674.
7. Solomon, GF. Stress and antibody response in rats. Int. Arch. Allerg. Appl. Immun. 1969; 35: 97-104.
8. Kubera M, Kenis G, Bosnians E, Kajta M, Basta-Kaim A, Scharpe S, Budziszewska B, Maes M. Stimulatory effect of antidepressants on the production of IL-6. Int. Immunopharmacol. 2004; 4(2): 185-192.
9. Kubera M, Kenis G, Bosnians E, Zieba A, Dudek D, Nowak G, Maes M. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol. J. Pharmacol. 2000; 52 (3): 237-241.
10. Kubera M, Simbirtsev A, Mathison R, Maes M. Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice. Psychiatry Res. 2000; 96 (3): 255-266.
11. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005; 29(2): 201-217.
12. Raison CL, Miller AH. The neuroimmunology of stress and depression. Semin. Clin. Neuropsychiatry 2001; 6(4): 277-294.
13. Da̧bkowska M, Rybakowski J. Stres, depresja i schizofrenia w aspekcie psychoimmunologicznym. Psychiatr. Pol. 1992; 26 (5): 347-356.
14. Bujniewicz E. Wspotdziatanie ukladu immunologicznego z neuroendokrynowym-znaczacarola interleukiny-1 i b-endorfiny. Diagnost. Labor. 2002; 38: 223-236.
15. Jakobisiak M. Immunologia. Warszawa: Wydawnictwo Naukowe PWN; 2000.
16. Mealy K, Barry M, O'Mahony L, Sheehan S, Burke P, Mc Cormack C, Whitehead AS, Bouchier-Hayes D. Effects of human recombinant growth hormone (rhGH) on inflammatory responses in patients undergoing abdominal aortic aneurysm repair. Intens. Care Med. 1998; 24(2): 128-131.
17. Stokłosa T. Powia̧zania miȩdzy układem immunologicznym i neuroendokrynowym. Klinika 1995; 3: 18.
18. Breder CD, Dinarello CA, Saber CB. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988; 240: 321-324.
19. Hopkins SJ, Rothwell NJ. Cytokines and the nervous system. I. Expression recognition. Trends Neurose. 1995; 18: 83-88.
20. Song C, Dinan T, Leonard BE. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affect. Disord. 1994; 30(4): 283-288.
21. Brambilla F, Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr. Scand. 1998; 97: 309-313.
22. Frommberger UH, Bauer J, Haselbauer P, Fraulin A, Riemann D, Berger M. Interleukin-6 (IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurose. 1997; 247 (4): 228-233.
23. Inglot A, Leszek J, Piasecki E, Sypula A. Interferon responses in schizophrenia and major depressive disorders. Biol. Psychiatry 1994; 35: 464-473.
24. Kubera M, Kenis G, Bosnians E, Ziȩba A, Dudek D, Nowak G, Macs M. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol. J. Pharmacol. 2000; 52: 237-241.
25. Kubera M, Lin AH, Kenis G, Bosnians E, van Bockstaele D, Maes M. Anti-inflammatory effects ofantidepressants through suppression of the interferon-gamma-interleukin-10 production ration. J. Clin. Psychopharmacol. 2001; 21: 199-206.
26. Maes M, Bosnians E, de Jongh R, Kenis G, Yandoolaeghe E, Neels H. Increased serum IL-6 and IL-I receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853-858.
27. Maes M, Meltzer HY, Bosnians E, Bergmans R, Yandoolaeghe E, Ranjan R, Desnyder R. Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferring receptor in major depression. J. Affec. Disord. 1995; 34: 301-309.
28. Maes M, Scharpe S, Meltzer HY, Okayli G, Bosnians E, D'Hondt P, Vanden Bossche BV, Cosyns P. Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response. Psychiatry Res. 1994; 54(2): 143-160.
29. Owen BM, Eccleston D, Ferrier IN, Young AH. Raised levels of plasma IL-I beta in major and postviral depression. Acta Psychiatr. Scand. 2001; 103: 161-162.
30. Stuźewska A, Rybakowski J, Sobieska M, Bosnians E, Pollet H, Wiktorowicz K. Increased levels of alpha-1-acidglycoprotein and IL-6 in refractorv depression. Depr. 1995; 3: 170-175.
31. Słuźewska A, Rybakowski J, Sobieska M, Wiktorowicz K. Concentrations and microheterogenity glycophorms of alpha-1-acid glycoprotein in major depression. J. Affec. Disord. 1996; 39: 149-155.
32. Song C, Dinan T, Leonard BE. Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J. Affec. Disord. 1994; 30: 283-288.
33. Maes M, Smith R, Christophe A, Vandoolaeghe E, van Gastel A, Neels H, Demedts P, Wauters A, Meltzer HY. Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr. Scand. 1997; 95 (3): 212-221.
34. Leonard BE. The immune system, depression and the action of antidepressants. Progr. Neuropsychopharmacol. Biol. Psychiatry 2001; 25: 767-780.
35. Vollmer-Conna U, Fazou C, Cameron B, Li H, Brennan C, Luck L, Davenport T, Wakefield D, Hickie I, Lloyd A. Production of pro-inflammatory cytokines correlates with the symptoms of acute sickness behaviour in humans. Psychol. Med. 2004; 34(7): 1289-1297.
36. Trzonkowski P, Myśliwska J, Godlewska B, Szmit E, Lukaszuk K, Wiȩckiewicz J, Brydak L, Machała M, Landowski J, Myśliwski A. Immune consequences of the spontaneous pro-inflammatory status in depressed elderly patients. Brain Behav. Immun. 2004; 18(2): 135-148.
37. Calabrese JR, Kling MA, Gold PW. Alterations in immunocompetence during stress, bereavement, and depression: focus on neuroendocrine regulation. Am. J. Psychiatry 1987; 144(9): 1123-1134.
38. Twardowska K, Rybakowski J. Oś limbiczno-podwzgórzowo- przysadkowo-nadnerczowa w depresji. Psychiatr. Pol. 1996; 30 (5): 741-756.
39. Deger O, Bekaroglu M, Orem A, Orem S, Uluutku N, Soylu C. Polymorphonuclear (PMN) elastase levels in depressive disorders. Biol. Psychiatry 1996; 39(5): 357-363.
40. Maes M, Lambrechts J, Bosmans E, Jacobs J, Suy E, Vandervorst C, de Jonckheere C, Minner B, Raus J. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol. Med. 1992; 22(1): 45-53.
41. Maes M, Scharpe S, Meltzer HY, Cosyns P. Relationships between increased haptoglobin plasma levels and activation of cell-mediated immunity in depression. Biol. Psychiatry 1993; 34 (10): 690-701.
42. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatr. Scand. 1996; 94 (3): 198-204.
43. Berk M, Wadee AA, Kuschke RH, O'Neill-Kerr A. Acute phase proteins in major depression, J. Psychosom. Res. 1997; 43(5): 529-534.
44. Stużewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K. Interleukin-6 serum levels in depressed patients before and after treatment withfluoxetine. Ann. NY Acad. Sc. 1995 (21); 762: 474-476.
45. Song C, Lin A, Bonaccorso S, Heide C, Verkerk R, Kenis G, Bosnians E, Scharpe S, Whelan A, Cosyns P, de Jongh R, Maes M. The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression. J. Affect. Disord. 1998; 49 (3): 211-219.
46. Maes M, Bosnians E, Meltzer HY, Schärpe S, Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression? Am. J. Psychiatry 1993; 150 (8): 1189-1193.
47. Maes M, Bosnians E, Suy E, Vandervorst C, de Jonckheere C, Raus J. Depression-related disturbances in mitogen-induced lymphocyte responses and interleukin-1 beta and soluble interleukin-2 receptor production. Acta Psychiatr. Scand. 1991; 84 (4): 379-386.
48. Maes M, Scharpe S, Meltzer HY, Bosnians E, Suy E, Calabrese J, Cosyns P. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 1993; 49(1): 11-27.
49. Seidel A, Arolt V, Hunstiger M, Rink L, Behnisch A, Kirchner H. Cytokine production and serum proteins in depression. Scand. J. Immunol. 1995; 41(6): 534-538.
50. Zhou D, Kusnecov AW, Shurin MR, de Paoli M, Rabin BS. Exposure to physical and psychological Stressors elevates plasma interleukin 6: relationship to the activation of hypothalamicpituitary-adrenal axis. Endocrinol. 1993; 133 (6): 2523-2530.
51. Kubera M, Symbirtsev A, Basta-Kaim A, Borycz J, Roman A, Papp M, Claesson M. Effect of chronic treatment with imipramine on interleukin 1 and interleukin 2 production by splenocytes obtained from rats subjected to a chronic mild stress model of depression. Pol. J. Pharmacol. 1996; 48 (5): 503-506.
52. Shintani F, Nakaki T, Kanba S, Kato R, Asai M. Role of interleukin-1 in stress responses. A putative neurotransmitter. Mol. Neurobiol. 1995; 10 (1): 47-71.
53. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, Yerkerk R, Meltzer H, Maes M. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 2002; 22: 86-90.
54. Green AR, Curzon G. Decrease of 5-hydroxytryptamine in the brain provoked by hydrocortisone and its prevention by allopurinol. Nature 1968; 220 (172): 1095-1097.
55. Maes M, Jacobs M-P, Suy E, Minner B, Leclercq C, Christiaens F, Raus J. Suppressant effects of dexamethasone on the availability of plasma L-tryptophan and tyrosine in healthy controls and in depressed patients. Acta Psychiatr. Scand. 1990; 81: 19-23.
56. Lesch K-P, Mayer S, Disselkamp-Tietze J, Hoh A, Wiesmann M, Osterheider M, Schulte HM. 5-HT1A receptor responsivity in unipolar depression: evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol. Psychiatry 1990; 28: 620-628.
57. Deakin JF, Pennell I, Upadhyaya AJ, Lofthouse R. A neuroendocrine study of 5HT function in depression: evidence for biological mechanisms of endogenous and psychosocial causation. Psychopharmacol. 1990; 101: 85-92.
58. Kuroda Y, Mikuni M, Ogawa T, Takahashi K. Effect of ACTH, adrenalectomy and the combination treatment on the density of 5-HT2 receptor binding sites in neocortex of rat forebrain and 5-HT2 receptor-mediated wet-dog shake behaviors. Psychopharmacol. 1992; 108: 27-32.
59. Dantzer R. Cytokine-induced sickness behaviour: Where do we stand? Brain. Behav. Immun. 2001; 15: 7-24.
60. Smith RS. The macrophage theory of depression. Med. Hypoth. 1991; 35(4): 298-306.
61. Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH, Ganapathy V. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem. Biophys. Res. Commun. 1995; 216(2): 560-567.
62. Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int. 1998; 33(3): 251-254.
63. Cunningham ET Jr, de Souza EB. Interleukin I receptors in the brain and endocrine tissues. Immunol. Today 1993; 14(4): 171-176.
64. Lieb J, Karmali R, Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostagl. Leukot. Med. 1983; 10 (4): 361-367.
65. Manku MS, Mtabaji JP, Horrobin DF. Effects of prostaglandins on baseline pressure and responses to noradrenaline in a perfused rat mesenteric artery preparation. PGE1 as an antagonist of PGE2. Prostagl. 1977; 13 (4): 701-709.
66. Leonard BE. The immune system, depression and the action of antidepressants. Progr. Neuropsychopharm. Biol. Psychiatry 2001; 25: 767-780.
67. Lieb J. Antidepressants, eicosanoids and the prevention and treatment of cancer. A review. Prostagl. Eukotr. Essent. Fatty Acids 2001; 65: 233-239.
68. Lieb J, Karmali R, Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostagl. Leuk. Med. 1983; 10 (4): 361-367.
69. Ansell D, Belch JJ, Forbes CD. Depression and prostacyclin infusion. Lancet 1986; 2 (8505): 509.
70. Ansar AS, Penhale WJ, Talal N. Sex hormones, immune responses, and autoimmune diseases. Mechanisms of sex hormone action. Am. J. Pathol. 1985; 121 (3): 531-551.
71. Athreya BH, Pletcher J, Zulian F, Weiner DB, Williams WV. Subset-specific effects of sex hormones and pituitary gonadotropins on human lymphocyte proliferation in vitro. Clin. Immunol. Immunopathol. 1993; 66(3): 201-211.
72. Knapp PH, Levy EM, Giorgi RG, Black PH, Fox BH, Heeren TC. Short-term immunological effects of induced emotion. Psychosom. Med. 1992; 54(2): 133-148.
73. Maes M, Smith RS. Fatty acids, cytokines, and major depression. Biol. Psychiatry 1998; 43(5): 313-314.
74. Maes M, Delange J, Ranjan R, Meltzer HY, Desnyder R, Cooremans W, Scharpe S. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997; 66(1): 1-11.
75. Lee RE. The influence of psychotropic drugs on prostaglandin biosynthesis. Prostagl. 1974; 5 (1): 63-68.
76. Hong SL, Carty T, Deykin D. Tranylcypromine and 15- hydroperoxyarachidonate affect arachidonic acid release in addition to inhibition of prostacydin synthesis in calf aortic endothelial cells. J. Biol. Chem. 1980; 255 (20): 9538-9540.
77. Mak O, Chen S. Effects of two antidepressant drugs - imipramine and amitriptyline on the enzyme activity of 15-hydroxyprostaglandin dehydrogenase purified from brain, lung, liver and kidney of mouse. Progr. Lipid Res. 1986; 25: 153-155.
78. Jackson JC, Walker RF, Brooks WH, Roszman TL. Specific uptake of serotonin by murine macrophages. Life Sc. 1988; 42 (17): 1641-1650.